Aerobic exercise's effect on immune response in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates how aerobic exercise influences the mobilization and functionality of anticancer immune cells in patients undergoing treatment for non-metastatic breast or colorectal cancer. The study aims to determine whether exercise can enhance the migratory capacity of immune cells, such as natural killer cells and cytotoxic T lymphocytes, and whether the intensity of exercise affects this response. By examining the relationship between exercise and immune activation, the trial seeks to explore the potential of exercise as an adjunct to cancer immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of non-metastatic breast or colon cancer
* Age between 40 and 70
* Have started chemotherapy or immunotherapy treatment and have at least three treatments remaining in the cycle
* ECOG stage 0 to 1
* Be able to perform moderate-intensity aerobic exercise (MOD) or EPI type cycling according to the established prescription and without experiencing pain in connection with the bicycle saddle

Exclusion Criteria:

* Orthopedic, cardiac or metabolic limitation preventing safe aerobic exercise
* Non-controlled health condition
* Use of beta-blockers
* Planned surgery during the study period.

Where it's running

• Research Center on Aging
  Sherbrooke, Quebec, Canada Recruiting
• Research Center on Aging
  Sherbrooke, Quebec, Canada Not yet recruiting

Study contacts

• Principal investigator: Eléonor Riesco, PhD — University of Sherbrooke, Faculty of Physical Activity Sciences, Department of Kinanthropology
• Study coordinator: Eléonor Riesco, PhD
• Email: eleonor.riesco@usherbrooke.ca
• Phone: 819-821-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Oral, Fecal and Tumor Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

  This study tests how the oral, gut, and tumor microbiomes relate to response to first-line immunotherapy in Colombian adults with advanced solid cancers.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07676461

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

• Targeted radiopharmaceuticals for GRPR-positive cancers in adults

  A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.

  Recruiting Phase 1 Alpha-9 Oncology USA Inc. · Melbourne N., Victoria and 1 other locations · NCT07661641

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.